An error appeared in the 15 August 2022 issue of the journal (Avery et al. “Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial.” Clin Infect Dis; 75(4): 690–701. https://doi.org/10.1093/cid/ciab988). The “Discussion” section of the paper currently states: “A higher study discontinuation rate before week 8 in the IAT group was also observed in the study. These discontinuations were primarily due to adverse events and toxicities known to be associated with available anti-CMV agents. Sensitivity analyses (Supplementary Table 2) were performed to address this potential bias.” The reference in the previous sentence should be to Supplementary Table 3, not Supplementary Table 2.
The authors regret the error.